IgG Subclass Switch in Volunteers Repeatedly Immunized with the Full-Length Merozoite Surface Protein 1 (MSP1).

Vaccines are highly effective tools against infectious diseases and are also considered necessary in the fight against malaria. Vaccine-induced immunity is frequently mediated by antibodies. We have recently conducted a first-in-human clinical trial featuring SumayaVac-1, a malaria vaccine based on the recombinant, full-length merozoite surface protein 1 (MSP1) formulated with GLA-SE as an adjuvant.